veludacigib

An orally bioavailable inhibitor of diacylglycerol kinase zeta (DGKzeta), with potential antineoplastic activity. Upon oral administration, veludacigib inhibits the activity of DGKzeta. This prevents the phosphorylation of diacylglycerol (DAG) to phosphatidic acid (PA), and modulates the DAGzeta-regulated cellular signaling pathways. This may inhibit the proliferation of tumor cells in which DGKzeta is overactivated. DGKzeta is overexpressed in certain cancer cells and plays an important role in tumor cell survival. DAGzeta may also play a key role in tumor immunosuppression.